Organigram has entered into a supply agreement to provide dried Medical Cannabis flower to 4C LABS, a healthcare, technology, and pharmaceutical company in the United Kingdom.
Under the terms of the Agreement, the Company expects to supply approximately 600 kilograms of high-quality, indoor-grown dried flower product to 4C LABS within the first year of the Agreement and grant 4C LABS strain exclusivity within the geographical boundaries of the United Kingdom & Channel Islands for as long as minimum purchase commitments are satisfied.
“Medical Cannabis has been legal in the UK since 2018. However, due to significant energy cost premiums compared to Canada, access to consistent, high-quality products in this market is limited, making importing Medical Cannabis an attractive option for this growing market,” says Beena Goldenberg, Chief Executive Officer of Organigram. “We are excited to partner with 4C LABS to increase access to Medical Cannabis for UK Medical Cannabis patients.”
“4C LABS is focused on delivering a value proposition to UK patients, 4C LABS provides top quality products, industry-leading pricing, best in class customer service, and a robust supply chain. says Greg Dobbin, Chief Executive Officer of 4C LABS. “We are excited to bring Organigram products to the UK & Channel Islands.”
For more information: